Search
Perphenazine
go.drugbank.com/drugs/DB00850ApprovedInvestigationalAn antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Oxyphencyclimine
go.drugbank.com/drugs/DB00383ApprovedOxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalUnlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and
Ioxaglic acid
go.drugbank.com/drugs/DB09313ApprovedWithdrawnThis drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. … Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opaque in its appearance on x-ray film, improving the visualization of important structures and organs during angiography, arteriography
Categories: X-Ray Contrast Activity, X-Ray Contrast Media, IodinatedEtynodiol
go.drugbank.com/drugs/DB13866ExperimentalEtynodiol (INN), or ethynodiol (BAN) is a steroidal progestin related to norethisterone which was never marketed.
Categories: Genito Urinary System and Sex Hormones, Sex Hormones and Modulators of the Genital SystemSynonyms: (3β,17α)-19-Norpregn-4-en-20-yne-3,17-diolDeutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalThe most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions [A32046
Poa pratensis pollen
go.drugbank.com/drugs/DB10366ApprovedPoa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]